Bam Bam | Universitas Narotama (original) (raw)
Papers by Bam Bam
Inorganic Chemistry, 2010
The first examples of the incorporation of the boraamidinate ligand into lanthanide complexes hav... more The first examples of the incorporation of the boraamidinate ligand into lanthanide complexes have been prepared by reaction of equimolar amounts of [Li(2)][PhB(NDipp)(2)] and LnCl(3) in tetrahydrofuran (THF), which produces "ate" complexes of the form {[Li(THF)(4)][bamLnCl(2)(THF)]}(2) [Ln = Y (9a), Pr (9b), Nd (9c), Sm (9d), Ho (9e), Er (9f), Yb (9g)] through the inclusion of the LiCl by-product. The isostructural complexes 9a-g were characterized in the solid state by X-ray crystallography, which revealed ion-separated complexes composed of a dimeric anion with a terminal and a bridging chloride ligand on each metal center and a tetrasolvated cation, [Li(THF)(4)](+). In solution, the yttrium complex 9a was characterized by multinuclear ((1)H, (13)C, (7)Li, and (11)B) NMR spectroscopy. The (1)H and (7)Li NMR spectra of the paramagnetic complexes 9b-9d showed broad resonances, but NMR spectra could not be obtained for 9e-g. The complexes 9a-g are readily soluble in THF, but insoluble in diethyl ether and hexane. The reaction of {[Li(THF)(4)][bamLnCl(2)(THF)]}(2) (Ln = Y, Sm) with an excess of trimethysilyl trifluoromethanesulfonate (TMSOTf) generates the dimeric neutral complexes {bamLnCl(THF)(2)}(2), which have been characterized by (1)H NMR and X-ray crystallography.
Bookmarks Related papers MentionsView impact
Digestive Diseases and Sciences, 2001
Bile acid malabsorption (BAM) has been described in patients with collagenous colitis. There are ... more Bile acid malabsorption (BAM) has been described in patients with collagenous colitis. There are no similar studies in lymphocytic colitis. The possibility that BAM might not necessarily be part of the microscopic colitis process and that both entities could simply be concomitant has not been evaluated. Our aim was to assess the frequency and severity of BAM in patients with microscopic colitis as well as in patients with previously unexplained functional chronic diarrhea. Likewise, we wanted to investigate the effect of cholestyramine on the induction and maintenance of remission of these conditions. A [75Se]HCAT abdominal retention test was performed in 26 patients with collagenous colitis, 25 with lymphocytic colitis, and 32 with previously unexplained functional chronic diarrhea. Patients with microscopic colitis who had BAM as well as a subgroup of eight collagenous colitis patients without BAM received treatment with cholestyramine. All patients with previously unexplained chronic diarrhea who had BAM were treated with cholestyramine. Twenty-two (43.1%) patients with microscopic colitis and 24 (75%) patients with previously unexplained functional chronic diarrhea presented with BAM. The frequency of BAM was higher in lymphocytic colitis than in collagenous colitis (60% vs 27%; P = 0.025). Cholestyramine induced clinical remission in 19 of 22 patients with microscopic colitis and BAM, none of eight patients with collagenous colitis without BAM, and all patients with previously unexplained chronic diarrhea and BAM. In conclusion, BAM seems to be common in patients with microscopic colitis—mainly in lymphocytic colitis—and in those with previously unexplained functional chronic diarrhea, suggesting that idiopathic BAM and microscopic colitis are often concomitant conditions. In this setting, cholestyramine seems to be highly effective in stopping diarrhea.
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Inorganic Chemistry, 2010
The first examples of the incorporation of the boraamidinate ligand into lanthanide complexes hav... more The first examples of the incorporation of the boraamidinate ligand into lanthanide complexes have been prepared by reaction of equimolar amounts of [Li(2)][PhB(NDipp)(2)] and LnCl(3) in tetrahydrofuran (THF), which produces "ate" complexes of the form {[Li(THF)(4)][bamLnCl(2)(THF)]}(2) [Ln = Y (9a), Pr (9b), Nd (9c), Sm (9d), Ho (9e), Er (9f), Yb (9g)] through the inclusion of the LiCl by-product. The isostructural complexes 9a-g were characterized in the solid state by X-ray crystallography, which revealed ion-separated complexes composed of a dimeric anion with a terminal and a bridging chloride ligand on each metal center and a tetrasolvated cation, [Li(THF)(4)](+). In solution, the yttrium complex 9a was characterized by multinuclear ((1)H, (13)C, (7)Li, and (11)B) NMR spectroscopy. The (1)H and (7)Li NMR spectra of the paramagnetic complexes 9b-9d showed broad resonances, but NMR spectra could not be obtained for 9e-g. The complexes 9a-g are readily soluble in THF, but insoluble in diethyl ether and hexane. The reaction of {[Li(THF)(4)][bamLnCl(2)(THF)]}(2) (Ln = Y, Sm) with an excess of trimethysilyl trifluoromethanesulfonate (TMSOTf) generates the dimeric neutral complexes {bamLnCl(THF)(2)}(2), which have been characterized by (1)H NMR and X-ray crystallography.
Bookmarks Related papers MentionsView impact
Digestive Diseases and Sciences, 2001
Bile acid malabsorption (BAM) has been described in patients with collagenous colitis. There are ... more Bile acid malabsorption (BAM) has been described in patients with collagenous colitis. There are no similar studies in lymphocytic colitis. The possibility that BAM might not necessarily be part of the microscopic colitis process and that both entities could simply be concomitant has not been evaluated. Our aim was to assess the frequency and severity of BAM in patients with microscopic colitis as well as in patients with previously unexplained functional chronic diarrhea. Likewise, we wanted to investigate the effect of cholestyramine on the induction and maintenance of remission of these conditions. A [75Se]HCAT abdominal retention test was performed in 26 patients with collagenous colitis, 25 with lymphocytic colitis, and 32 with previously unexplained functional chronic diarrhea. Patients with microscopic colitis who had BAM as well as a subgroup of eight collagenous colitis patients without BAM received treatment with cholestyramine. All patients with previously unexplained chronic diarrhea who had BAM were treated with cholestyramine. Twenty-two (43.1%) patients with microscopic colitis and 24 (75%) patients with previously unexplained functional chronic diarrhea presented with BAM. The frequency of BAM was higher in lymphocytic colitis than in collagenous colitis (60% vs 27%; P = 0.025). Cholestyramine induced clinical remission in 19 of 22 patients with microscopic colitis and BAM, none of eight patients with collagenous colitis without BAM, and all patients with previously unexplained chronic diarrhea and BAM. In conclusion, BAM seems to be common in patients with microscopic colitis—mainly in lymphocytic colitis—and in those with previously unexplained functional chronic diarrhea, suggesting that idiopathic BAM and microscopic colitis are often concomitant conditions. In this setting, cholestyramine seems to be highly effective in stopping diarrhea.
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact